Bicycle Therapeutics(DE:50BA)
€3.22+0.02 (+4.55%)
DE:50BA
Bicycle Therapeutics financials statements
€3.22
At close:+0.02 (+4.55%)
Bicycle Therapeutics (50BA) Ratios
1 Followers
Bicycle Therapeutics Ratios
DE:50BA's free cash flow for Q3 2026 was $-40.61M. For the 2026 fiscal year, DE:50BA's free cash flow was decreased by $-305.00K and operating cash flow was $-40.30M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.98 | 13.81 | 8.08 | 6.92 | 12.65 |
| Quick Ratio | 11.98 | 13.81 | 8.08 | 6.92 | 12.65 |
| Cash Ratio | 11.02 | 13.08 | 7.57 | 6.36 | 12.11 |
| Solvency Ratio | -1.97 | -0.99 | -0.78 | -0.78 | -0.49 |
| Operating Cash Flow Ratio | -4.38 | -2.45 | -0.87 | -1.61 | -0.41 |
| Short-Term Operating Cash Flow Coverage | -90.59 | 0.00 | -12.43 | 0.00 | 0.00 |
| Net Current Asset Value | $ 575.26M | $ 764.80M | $ 337.46M | $ 229.56M | $ 325.02M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.01 | 0.08 | 0.11 | 0.09 |
| Debt-to-Equity Ratio | 0.03 | 0.01 | 0.12 | 0.16 | 0.13 |
| Debt-to-Capital Ratio | 0.03 | 0.01 | 0.11 | 0.14 | 0.11 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.08 | 0.10 | 0.08 |
| Financial Leverage Ratio | 1.18 | 1.21 | 1.60 | 1.52 | 1.39 |
| Debt Service Coverage Ratio | -71.69 | -92.56 | -22.71 | -31.60 | -20.92 |
| Interest Coverage Ratio | -1202.51 | -121.31 | -58.21 | -34.88 | -21.99 |
| Debt to Market Cap | 0.01 | 0.00 | 0.06 | 0.03 | 0.02 |
| Interest Debt Per Share | 0.26 | 0.19 | 1.35 | 1.61 | 1.89 |
| Net Debt to EBITDA | 2.88 | 5.28 | 2.63 | 2.75 | 6.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | -390.34% | -480.13% | 100.00% | 100.00% |
| EBIT Margin | -301.16% | -487.78% | -704.13% | -766.76% | -559.96% |
| EBITDA Margin | -292.32% | -467.45% | -679.86% | -741.26% | -547.91% |
| Operating Profit Margin | -341.28% | -594.96% | -704.13% | -806.56% | -560.98% |
| Pretax Profit Margin | -301.45% | -492.69% | -664.32% | -789.88% | -585.47% |
| Net Profit Margin | -301.66% | -479.18% | -669.72% | -779.35% | -571.25% |
| Continuous Operations Profit Margin | -301.66% | -479.18% | -669.72% | -779.35% | -571.25% |
| Net Income Per EBT | 100.07% | 97.26% | 100.81% | 98.67% | 97.57% |
| EBT Per EBIT | 88.33% | 82.81% | 94.35% | 97.93% | 104.36% |
| Return on Assets (ROA) | -30.51% | -17.67% | -30.35% | -27.45% | -13.93% |
| Return on Equity (ROE) | -35.90% | -21.31% | -48.71% | -41.63% | -19.30% |
| Return on Capital Employed (ROCE) | -37.50% | -23.59% | -36.12% | -32.65% | -14.79% |
| Return on Invested Capital (ROIC) | -37.34% | -22.80% | -35.79% | -31.94% | -14.36% |
| Return on Tangible Assets | -30.51% | -17.67% | -30.35% | -27.45% | -13.93% |
| Earnings Yield | -44.64% | -20.74% | -28.07% | -12.84% | -4.38% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.04 | 0.99 | 1.12 | 0.68 | 0.98 |
| Payables Turnover | 0.00 | 10.95 | 11.99 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 3.31 | 2.05 | 0.97 | 0.44 | 0.66 |
| Asset Turnover | 0.10 | 0.04 | 0.05 | 0.04 | 0.02 |
| Working Capital Turnover Ratio | 0.10 | 0.05 | 0.07 | 0.04 | 0.04 |
| Cash Conversion Cycle | 178.99 | 335.58 | 294.82 | 535.20 | 371.65 |
| Days of Sales Outstanding | 178.99 | 368.91 | 325.26 | 535.20 | 371.65 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 33.33 | 30.44 | 0.00 | 0.00 |
| Operating Cycle | 178.99 | 368.91 | 325.26 | 535.20 | 371.65 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.60 | -2.83 | -1.70 | -2.90 | -0.59 |
| Free Cash Flow Per Share | -3.64 | -2.85 | -1.79 | -3.54 | -0.67 |
| Dividend Paid and CapEx Coverage Ratio | -106.00 | -133.38 | -20.70 | -4.54 | -7.29 |
| Capital Expenditure Coverage Ratio | -106.00 | -133.38 | -20.70 | -4.54 | -7.29 |
| Operating Cash Flow Coverage Ratio | -14.25 | -17.35 | -1.35 | -1.94 | -0.33 |
| Operating Cash Flow to Sales Ratio | -3.44 | -4.67 | -2.25 | -5.95 | -1.26 |
| Free Cash Flow Yield | -51.38% | -20.37% | -9.88% | -11.97% | -1.10% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.24 | -4.82 | -3.56 | -7.79 | -22.83 |
| Price-to-Sales (P/S) Ratio | 6.76 | 23.10 | 23.85 | 60.70 | 130.42 |
| Price-to-Book (P/B) Ratio | 0.80 | 1.03 | 1.73 | 3.24 | 4.41 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.95 | -4.91 | -10.12 | -8.35 | -90.67 |
| Price-to-Operating Cash Flow Ratio | -1.96 | -4.95 | -10.61 | -10.20 | -103.12 |
| Price-to-Earnings Growth (PEG) Ratio | -0.26 | 0.11 | -0.11 | -0.18 | -60.73 |
| Enterprise Value Multiple | 0.57 | 0.33 | -0.88 | -5.44 | -17.65 |
| Enterprise Value | -120.09M | -55.12M | 162.04M | 583.13M | 1.13B |
| EV to EBITDA | 0.57 | 0.33 | -0.88 | -5.44 | -17.65 |
| EV to Sales | -1.65 | -1.56 | 6.01 | 40.32 | 96.71 |
| EV to Free Cash Flow | 0.48 | 0.33 | -2.55 | -5.55 | -67.24 |
| EV to Operating Cash Flow | 0.48 | 0.33 | -2.67 | -6.77 | -76.46 |
| Tangible Book Value Per Share | 8.80 | 13.62 | 10.42 | 9.13 | 13.82 |
| Shareholders’ Equity Per Share | 8.80 | 13.62 | 10.42 | 9.13 | 13.82 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.03 | -0.01 | 0.01 | 0.02 |
| Revenue Per Share | 1.05 | 0.61 | 0.76 | 0.49 | 0.47 |
| Net Income Per Share | -3.16 | -2.90 | -5.08 | -3.80 | -2.67 |
| Tax Burden | 1.00 | 0.97 | 1.01 | 0.99 | 0.98 |
| Interest Burden | 1.00 | 1.01 | 0.94 | 1.03 | 1.05 |
| Research & Development to Revenue | 3.31 | 4.90 | 5.80 | 5.64 | 3.84 |
| SG&A to Revenue | 1.10 | 2.03 | 2.22 | 3.42 | 2.77 |
| Stock-Based Compensation to Revenue | 0.54 | 1.08 | 1.20 | 1.85 | 1.03 |
| Income Quality | 1.14 | 0.97 | 0.34 | 0.76 | 0.22 |
Currency in USD
